Abatacept plus MTX Treatment Confers Similar Clinical Efficacy Regardless of Baseline Rheumatoid Factor or CRP Status in the AIM Trial

被引：0
|
作者：
Russell, Anthony [1 ]
Sibilia, Jean [2 ]
Cantagrel, Alain [3 ]
Westhovens, Rene [4 ]
Gaillez, Corine [5 ]
Le Bars, Manuela [5 ]
Poncet, Coralie [6 ]
Elegbe, Ayanbola [7 ]
Kremer, Joel [8 ]
机构：
[1] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada
[2] Hop Hautepierre, Strasbourg, France
[3] CHU Rangueil, F-31054 Toulouse, France
[4] Katholieke Univ Leuven, Louvain, Belgium
[5] Bristol Myers Squibb, Paris, France
[6] Docs Int, Sevres, France
[7] Bristol Myers Squibb Co, Princeton, NJ USA
[8] Albany Med Coll, Albany, NY 12208 USA
来源：
JOURNAL OF RHEUMATOLOGY | 2012年 / 39卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
28
引用
收藏
页码：1714 / 1715
页数：2
相关论文
共 19 条
  • [1] ABATACEPT CONFERS CLINICAL EFFICACY REGARDLESS OF BASELINE CRP STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE IN THE AIM TRIAL
    Sibilia, Jean
    Flipo, Rene Marc
    Combe, Bernard
    Gaillez, Corine
    Le Bars, Manuela
    Poncet, Coralie
    Elegbe, Ayanbola
    Westhovens, Rene
    RHEUMATOLOGY, 2012, 51 : 124 - 125
  • [2] CLINICAL EFFICACY OF ABATACEPT AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE ACCORDING TO BASELINE RHEUMATOID FACTOR STATUS IN THE ATTEST TRIAL
    Dougados, Maxime
    Gaillez, Corine
    Le Bars, Manuela
    Poncet, Coralie
    Elegbe, Ayanbola
    Schiff, Michael
    RHEUMATOLOGY, 2012, 51 : 127 - 127
  • [3] Abatacept improves clinical responses regardless of baseline physical function: Results from the AIM trial.
    Russell, A
    Emery, P
    Kafka, SP
    Aranda, R
    Becker, JC
    Mokliatchouk, O
    Westhovens, R
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S543 - S543
  • [4] Long-term efficacy of abatacept through 2 years of treatment in rheumatoid arthritis patients in the aim trial
    Kremer, J.
    Russell, A.
    Westhovens, R.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1630 - 1630
  • [5] Long-term efficacy of abatacept through 2 years of treatment in rheumatoid arthritis patients in the AIM trial.
    Kremer, J.
    Westhovens, R.
    Russell, A.
    Emery, P.
    Aranda, R.
    Becker, J-C
    Teng, J.
    Schmidely, N.
    Le Bars, M.
    Moreland, L.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S247 - S247
  • [6] Safety and efficacy of abatacept over 4 years of treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate in the AIM trial
    Kremer, J. M.
    Russell, A. S.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S308 - S309
  • [7] Safety and Efficacy of Abatacept Over 4 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in the AIM Trial
    Russell, A. S.
    Kremer, J. M.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2608 - 2609
  • [8] Long-term efficacy and safety of abatacept through 3 years of treatment in rheumatoid arthritis patients in the aim trial
    van Vollenhoven, Ronald
    Kremer, J.
    Westhovens, R.
    Luggen, M.
    Russell, A.
    Aranda, R.
    Becker, J-C
    Joshi, C.
    Gandhi, M.
    Genovese, M. C.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 51 - 51
  • [9] Decreased external home help use with improved clinical status in rheumatoid arthritis: An exploratory analysis of the abatacept in inadequate responders to methotrexate (AIM) trial
    Li, Tracy
    Gignac, Monique
    Wells, George
    Shen, Sophie
    Westhovens, Rene
    CLINICAL THERAPEUTICS, 2008, 30 (04) : 734 - 748
  • [10] DAS28(CRP) <3.2 ACHIEVED WITH OR WITHOUT A TNF INHIBITOR: DIFFERENCES IN RADIOGRAPHIC, CLINICAL, AND BIOMARKER OUTCOMES BETWEEN PLACEBO plus MTX AND GOLIMUMAB plus MTX TREATMENT AMONG MTX-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS
    Karpouzas, G. A.
    Emery, P.
    Fleischmann, R.
    Xu, S.
    Hsia, E. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 883 - 883
12